TWST

+ Watchlist + Portfolio

Twist Bioscience Corp.

Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $188.05
52-Week Range: $23.30 – $200.31
Market Cap: $12.51B
P/E (TTM): —
EPS (TTM): -2.23
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 26.53
PEG Ratio: —
Return on Equity: -29.59%
Return on Assets: -13.09%
Gross Margin: 51.96%
Operating Margin: -30.65%
Profit Margin: -31.66%
Current Ratio: 2.67
Debt/Equity: 0.24
Total Debt: $108.59M
Free Cash Flow: $-64.82M
Revenue Growth: 23.20%
Earnings Growth: —
Enterprise Value: $11.77B

TWST Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$203.56M	$245.11M	$312.97M	$376.57M
Cost of Revenue	$119.33M	$155.38M	$179.63M	$185.57M
Gross Profit	$84.23M	$89.73M	$133.35M	$191.00M
Research & Development	$120.31M	$106.89M	$90.85M	$80.28M
Selling, General & Admin	$212.95M	$189.74M	$218.40M	$246.98M
Operating Expenses	$333.26M	$296.63M	$309.25M	$327.26M
Operating Income	-$249.02M	-$206.90M	-$175.90M	-$136.26M
EBITDA	-$211.68M	-$177.59M	-$144.47M	-$111.41M
Pretax Income	-$228.27M	-$203.47M	-$208.17M	-$76.95M
Income Tax	-$10.41M	$1.15M	$560.00K	$719.00K
Net Income	-$217.86M	-$204.62M	-$208.73M	-$77.67M
Diluted EPS	-4.04	-3.60	-3.60	-1.30
Diluted Shares	53.88M	56.88M	58.02M	59.81M

TWST Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$378.69M	$286.47M	$226.32M	$183.05M
Receivables	$40.29M	$44.06M	$34.90M	$57.02M
Inventory	$39.31M	$32.06M	$24.08M	$28.31M
Current Assets	$596.48M	$424.26M	$346.78M	$332.97M
Total Assets	$961.38M	$776.40M	$614.32M	$641.86M
Current Liabilities	$90.66M	$73.32M	$71.01M	$91.41M
Total Debt	$94.91M	$94.07M	$85.03M	$75.57M
Total Liabilities	$171.99M	$152.97M	$141.63M	$168.90M
Retained Earnings	-$828.42M	-$1.03B	-$1.24B	-$1.32B
Shareholders' Equity	$789.38M	$623.43M	$472.69M	$472.96M
Working Capital	$505.82M	$350.93M	$275.77M	$241.56M

TWST Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$124.39M	-$142.47M	-$64.09M	-$47.63M
Capital Expenditure	-$101.86M	-$27.78M	-$5.08M	-$28.00M
Free Cash Flow	-$226.24M	-$170.25M	-$69.17M	-$75.63M
Depreciation & Amortisation	$16.51M	$29.31M	$31.43M	$24.85M
Stock-Based Compensation	$79.66M	$30.28M	$50.92M	$64.46M
Investing Cash Flow	-$232.93M	$50.61M	-$3.07M	-$24.76M
Financing Cash Flow	$270.53M	$911.00K	$6.89M	$28.54M
Share Repurchases	-$7.75M	-$4.41M	-$3.98M	-$16.00K
Net Change in Cash	-$86.78M	-$90.95M	-$60.27M	-$43.85M

TWST Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$92.79M	$96.06M	$99.01M	$103.70M	$110.72M	$118.38M
Cost of Revenue	$46.77M	$44.76M	$48.17M	$49.73M	$53.59M	$55.92M
Gross Profit	$46.03M	$51.30M	$50.84M	$53.97M	$57.12M	$62.45M
Research & Development	$23.92M	$18.05M	$17.01M	$17.13M	$19.70M	$18.02M
Selling, General & Admin	$63.67M	$63.37M	$63.76M	$69.94M	$76.08M	$80.71M
Operating Expenses	$87.59M	$81.42M	$80.77M	$87.07M	$95.78M	$98.73M
Operating Income	-$41.56M	-$30.12M	-$29.93M	-$33.10M	-$38.66M	-$36.28M
EBITDA	-$35.16M	-$24.05M	-$23.93M	-$26.91M	-$32.24M	-$29.50M
Pretax Income	-$39.15M	$20.58M	-$26.88M	-$30.25M	-$43.98M	-$34.74M
Income Tax	$175.00K	$191.00K	$257.00K	$253.00K	$43.00K	$311.00K
Net Income	-$39.33M	$20.39M	-$27.14M	-$30.51M	-$44.02M	-$35.05M
Diluted EPS	-0.66	0.33	-0.45	-0.50	-0.71	-0.56
Diluted Shares	59.65M	61.16M	60.42M	61.08M	61.70M	62.40M

TWST Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$210.44M	$201.37M	$183.05M	$148.59M	$122.67M	$117.44M
Receivables	$49.95M	$49.85M	$57.02M	$50.06M	$87.45M	$87.58M
Inventory	$20.86M	$25.94M	$28.31M	$32.92M	$33.52M	$35.16M
Current Assets	$338.44M	$339.78M	$332.97M	$303.88M	$323.44M	$321.30M
Total Assets	$595.62M	$643.61M	$641.86M	$638.09M	$676.21M	$672.44M
Current Liabilities	$74.98M	$87.07M	$91.41M	$80.44M	$119.98M	$120.25M
Total Debt	$80.30M	$78.15M	$75.57M	$98.05M	$95.84M	$93.59M
Total Liabilities	$155.51M	$165.41M	$168.90M	$181.99M	$221.12M	$226.70M
Retained Earnings	-$1.31B	-$1.29B	-$1.32B	-$1.35B	-$1.39B	-$1.43B
Shareholders' Equity	$440.11M	$478.20M	$472.96M	$456.10M	$455.09M	$445.74M
Working Capital	$263.47M	$252.71M	$241.56M	$223.44M	$203.46M	$201.04M

TWST Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$12.99M	-$1.40M	-$11.81M	-$24.81M	-$17.56M	$1.11M
Capital Expenditure	-$4.14M	-$9.16M	-$12.43M	-$9.97M	-$7.99M	-$9.76M
Free Cash Flow	-$17.13M	-$10.56M	-$24.24M	-$34.79M	-$25.55M	-$8.65M
Depreciation & Amortisation	$6.40M	$6.07M	$6.00M	$6.19M	$6.41M	$6.78M
Stock-Based Compensation	$20.33M	$16.06M	$16.08M	$13.27M	$18.94M	$18.18M
Investing Cash Flow	-$1.43M	-$9.40M	-$12.40M	-$9.93M	-$12.71M	-$10.20M
Financing Cash Flow	$3.20M	$1.83M	$5.57M	$298.00K	$4.14M	$3.79M
Share Repurchases	-$5.00K	-$3.00K	-$2.00K	-$2.00K	-$8.00K	-$6.00K
Net Change in Cash	-$11.22M	-$8.97M	-$18.64M	-$34.45M	-$26.13M	-$5.30M

Market Snapshot

About

Twist Bioscience is a synthetic biology company that manufactures synthetic DNA using its proprietary silicon platform. The company serves customers in healthcare, agriculture, industrial chemicals, and data storage markets with custom DNA sequences for research and commercial applications.